German firm Qiagen said it agreed to acquire DxS, a U.K.-based maker of genetic tests, in an effort to broaden its cancer diagnostics business. The deal entitles DxS to receive $95 million in cash from Qiagen and up to $35 million in additional payments if certain milestones are met.

Full Story:

Related Summaries